I am based at the Cancer Research UK Imperial Centre: Clinical Trials Section. I have 13 years experience working in cancer trials, primarily gynaecological malignancies. Since September 2019 I have been overseeing studies in ovary, breast and cancer of unknown primary, as well as working on pre- and post-funded studies approved by our trials oversight committee. Our team forms part of the Imperial Clinical Trials Unit (ICTU).
et al., 2015, Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control, Molecular Oncology, Vol:9, ISSN:1574-7891, Pages:791-805
et al., 2014, A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, Annals of Oncology, Vol:25, ISSN:0923-7534, Pages:1988-1995